Unable to display view head.php file not found.
 
 

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 35

ROCKET AF: Rivaroxaban vs Warfarin

The Figure shows the ITT analysis of the results.[97] For rivaroxaban vs warfarin these results were 2.1 vs 2.4 events per 100 patient-years, respectively.  The difference was just short of statistical nonsignificance, meaning that rivaroxaban was noninferior, but just short of superior, to warfarin; put another way, the efficacy of rivaroxaban was at least as good as the efficacy of warfarin

 Reiffel JA. Am J Med 2013; 126: 00-00.

Complete references for all slides

References

[97] Patel MR, Mahaffey KW, Garg J, et al; the ROCKET AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.

Unable to display view foot.php file not found.